Use of Real-World Evidence in Health Technology Assessments of Non-Oncology Rare Disease Therapies. [PDF]
J Mark Access Health PolicyBlandy O +5 more
europepmc +1 more source
The role of financial distress as a patient-relevant endpoint in early benefit assessments for oncology drugs: a mixed-methods document analysis. [PDF]
Int J Technol Assess Health CarePauge S +3 more
europepmc +1 more source
Discounting Practices in Cost-Effectiveness Analyses in Dentistry: A Systematic Review of Studies Published After 2020. [PDF]
Clinicoecon Outcomes ResMaruster R, Bornstein MM, Sendi P.
europepmc +1 more source
Jahrestherapiekosten in der frühen Nutzenbewertung - Implikationen aus der Kritik des IQWiG und den Beschlüssen des G-BA [PDF]
, 2014 Anderson, D
core +1 more source
The launch and diffusion of new patented medicines by therapeutic value. [PDF]
Health Aff SchZhang W +5 more
europepmc +1 more source
Radiographic progression-free survival as a surrogate endpoint for overall survival in first-line ARPi naïve metastatic castration-resistant prostate cancer. [PDF]
OncologistCastro E +7 more
europepmc +1 more source
Defining Comparators According to IQWiG’s Efficiency-Frontier Method [PDF]
Value in Health, 2020 openaire +2 more sources
Hospital-based real-world evidence in health technology assessment: insights from a scoping review of European, Australian and North American guidance and expert interviews. [PDF]
BMJ OpenAl-Khayat Z +3 more
europepmc +1 more source
Multi-stakeholder use of patient experience data (PED): current state and future opportunities for the application of PED to inform decision-making. [PDF]
J Patient Rep OutcomesKanu C +12 more
europepmc +1 more source